RS52492B - Molekuli koji se interspecijski specifično bispecifično vezuju - Google Patents

Molekuli koji se interspecijski specifično bispecifično vezuju

Info

Publication number
RS52492B
RS52492B RS20120412A RSP20120412A RS52492B RS 52492 B RS52492 B RS 52492B RS 20120412 A RS20120412 A RS 20120412A RS P20120412 A RSP20120412 A RS P20120412A RS 52492 B RS52492 B RS 52492B
Authority
RS
Serbia
Prior art keywords
epitope
species
cross
binding
specific bispecific
Prior art date
Application number
RS20120412A
Other languages
English (en)
Inventor
Matthias Klinger
Tobias Raum
Doris Rau
Roman Kischel
Ralf LUTTERBĂśSE
Patrick Hoffmann
Peter Kufer
Susanne Mangold
Original Assignee
Amgen Research (Munich) Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Research (Munich) Gmbh filed Critical Amgen Research (Munich) Gmbh
Priority claimed from PCT/EP2008/002663 external-priority patent/WO2008119566A2/en
Publication of RS52492B publication Critical patent/RS52492B/sr

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Polipeptid koji sadrži prvi vezivni domen, koji je antitelo sposobno da se veže za epitop CD3ε lanca čoveka i Callithrix jacchusa, Saguinus oedipusa ili Saimiri sciureusa, naznačen time, stoje taj epitop deo aminokiselinske sekvence sadržane u grupi koju čine SEQ ID br:2, 4, 6, ili 8 i sadrži najmanje aminokiselinsku sekvencu Gln-Asp-Gly-Asn-Glu, i drugi vezivni domen koji je u stanju da se veže za EGFR, Her2/neu ili IgE čoveka i/ili primata koji nisu šimpanze.Prijava sadrži još 17 patentnih zahteva.
RS20120412A 2007-04-03 2008-04-03 Molekuli koji se interspecijski specifično bispecifično vezuju RS52492B (sr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
EP07006988 2007-04-03
EP07006990 2007-04-03
US91366807P 2007-04-24 2007-04-24
EP07020641 2007-10-22
EP07020640 2007-10-22
EP07020646 2007-10-22
EP08004741 2008-03-13
PCT/EP2008/002663 WO2008119566A2 (en) 2007-04-03 2008-04-03 Cross-species-specific bispecific binders

Publications (1)

Publication Number Publication Date
RS52492B true RS52492B (sr) 2013-02-28

Family

ID=42582614

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20120412A RS52492B (sr) 2007-04-03 2008-04-03 Molekuli koji se interspecijski specifično bispecifično vezuju

Country Status (8)

Country Link
JP (1) JP2010524435A (sr)
DK (1) DK2155788T3 (sr)
ES (1) ES2390243T3 (sr)
NZ (1) NZ580746A (sr)
PT (1) PT2155788E (sr)
RS (1) RS52492B (sr)
RU (1) RU2535992C2 (sr)
SI (1) SI2155788T1 (sr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008119566A2 (en) * 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific bispecific binders
HUE040467T2 (hu) * 2007-04-03 2019-03-28 Amgen Res Munich Gmbh Keresztfaj-specifikus kötõdomén
WO2012066058A1 (en) * 2010-11-16 2012-05-24 Boehringer Ingelheim International Gmbh Agents and methods for treating diseases that correlate with bcma expression
WO2012158818A2 (en) * 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
SG10201509588TA (en) * 2011-05-21 2015-12-30 Macrogenics Inc CD3-Binding Molecules Capable Of Binding To Human And Non-Human CD3
WO2015095392A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Anti-cd3 antibodies and methods of use
EP3149041A1 (en) * 2014-05-28 2017-04-05 F. Hoffmann-La Roche AG Antibodies binding to human and cynomolgus cd3 epsilon
JP7020909B2 (ja) * 2014-07-25 2022-02-16 シトムクス セラピューティクス，インコーポレイティド 抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法
CA2952540C (en) * 2014-07-31 2022-06-21 Amgen Research (Munich) Gmbh Bispecific single chain antibody construct with enhanced tissue distribution
CN107709363A (zh) * 2015-05-01 2018-02-16 基因泰克公司 掩蔽抗cd3抗体和使用方法
EP3430058A4 (en) 2016-03-15 2019-10-23 Generon (Shanghai) Corporation Ltd. MULTISPECIFIC FAB FUSION PROTEINS AND USES THEREOF
US11466094B2 (en) 2016-11-15 2022-10-11 Genentech, Inc. Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
US10426424B2 (en) 2017-11-21 2019-10-01 General Electric Company System and method for generating and performing imaging protocol simulations
KR20200118065A (ko) 2018-02-08 2020-10-14 제넨테크, 인크. 이중특이적 항원-결합 분자 및 이의 사용 방법
US20230067182A1 (en) * 2019-11-29 2023-03-02 Boe Technology Group Co., Ltd. Data Processing Device and Method, and Computer Readable Storage Medium
KR20220113790A (ko) 2019-12-13 2022-08-16 제넨테크, 인크. 항-ly6g6d 항체 및 사용 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD272473B3 (de) * 1988-06-13 1993-01-21 Univ Leipzig Verfahren zur herstellung monoklonaler antikoerper gegen die epsilon-kettedes cd 3-antigens humaner t-lymphozyten
US7235641B2 (en) * 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies

Also Published As

Publication number Publication date
PT2155788E (pt) 2012-09-25
ES2390243T3 (es) 2012-11-07
JP2010524435A (ja) 2010-07-22
SI2155788T1 (sl) 2012-11-30
NZ580746A (en) 2012-05-25
DK2155788T3 (da) 2012-10-08
RU2009136913A (ru) 2011-06-20
RU2535992C2 (ru) 2014-12-20

Similar Documents

Publication Publication Date Title
RS52492B (sr) Molekuli koji se interspecijski specifično bispecifično vezuju
RS54900B1 (sr) Interspecijski specifično psmaxcd3 bispecifično jednolančano antitelo
RS53008B (sr) Interspecijski specifičan cd3-epsilon vezujući domen
NZ602209A (en) Cross-species-specific psmaxcd3 bispecific single chain antibody
AR109355A2 (es) Moléculas de unión al receptor ox40 humano
RS54675B1 (sr) Smeše monovalentne za vezivanje sa cd28 i metodi upotrebe
TW200745164A (en) Gene recombination antibodies composition
RU2019100481A (ru) Биспецифические антитела-ингибиторы контрольных точек
EP2987806A3 (en) Modified single variable domain antibodies with reduced binding to anti-drug-antibodies
RU2014144143A (ru) Химерные антигенные рецепторы, нацеленные на антиген созревания в-клеток
RS54359B1 (sr) Anti cd37 antitela
RS52484B (sr) Antitela na cd40
EA200870555A1 (ru) Слитые белки, их применение и способы их получения
NZ584838A (en) Novel antibodies which bind alpha5beta1 (fibronectin receptor) and uses thereof
CO5261584A1 (es) Anticuerpos para il-1 humana
RS54424B1 (sr) Humana antitela koja se vezuju za cxcr4 i njihove upotrebe
NZ590668A (en) TNF-alpha ANTAGONIST MULTI-TARGET BINDING PROTEINS
DE602005022830D1 (de) Weniger immunogene bindungsmoleküle
RS52775B (sr) Optimizovana antitela usmerena na cd19
SG10201807877TA (en) Hybrid immunoglobulin containing non-peptidyl linkage
RS54299B1 (sr) Sastavi i metode upotrebe terapijskih antitela
WO2005066867A3 (en) Modulators of cell-surface receptors of the ig-class
SG149004A1 (en) Inhibitors of type 2 vascular endothelial growth factor receptors
AR070202A1 (es) Anticuerpos anti- trkb mejorados
RS52769B (sr) Kompozicije i postupci za povećanje mineralizacije kostiju